Immatics Announces Proposed Public Offering
January 17 2024 - 4:01PM
Immatics Announces Proposed Public Offering
Houston, Texas and
Tuebingen, Germany, January 17, 2024 – Immatics
N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage
biopharmaceutical company active in the discovery and development
of T cell-redirecting cancer immunotherapies, announced today the
commencement of an underwritten public offering of its ordinary
shares. The offering is subject to market conditions and other
factors, and there can be no assurance as to whether or when the
offering may be completed, or as to the actual size or terms of the
offering.
Jefferies, BofA Securities and Leerink Partners
are acting as joint book-running managers for the offering.
A registration statement relating to the
securities has been filed with the U.S. Securities and Exchange
Commission (the “SEC”) and was declared effective on August 9,
2021. The offering will be made only by means of a prospectus
supplement and accompanying prospectus. A preliminary prospectus
supplement related to the offering has been filed with the SEC and
is available free of charge by visiting EDGAR on the SEC’s website
at www.sec.gov. Copies of the preliminary prospectus supplement and
the accompanying prospectus relating to the offering may be
obtained free of charge from
- Jefferies LLC, Attention: Equity
Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New
York, NY 10022, telephone: (877) 821-7388, email:
Prospectus_Department@Jefferies.com;
- BofA Securities, Attention:
Prospectus Department, NC1-022-02-25, 201 North Tryon Street,
Charlotte, NC 28255-0001, telephone: (800) 294-1322, email:
dg.prospectus_requests@bofa.com;
- Leerink Partners LLC, Attention:
Syndicate Department, 53 State Street, 40th Floor, Boston, MA
02109, telephone: (800) 808-7525, ext. 6105, email:
syndicate@leerink.com.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy these securities, nor
shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction. Any offers,
solicitations or offers to buy, or any sales of securities will be
made in accordance with the registration requirements of the
Securities Act of 1933, as amended.
- END -
About ImmaticsImmatics combines
the discovery of true targets for cancer immunotherapies with the
development of the right T cell receptors with the goal of enabling
a robust and specific T cell response against these targets. This
deep know-how is the foundation for our pipeline of Adoptive Cell
Therapies and TCR Bispecifics as well as our partnerships with
global leaders in the pharmaceutical industry. We are committed to
delivering the power of T cells and to unlocking new avenues for
patients in their fight against cancer.
Forward-Looking
StatementsCertain statements in this press release may be
considered forward-looking statements, including statements
regarding the proposed securities offering. Such forward-looking
statements are subject to risks, uncertainties, and other factors
which could cause actual results to differ materially from those
expressed or implied by such forward-looking statements. These
forward-looking statements are based upon estimates and assumptions
that, while considered reasonable by Immatics and its management,
are inherently uncertain. New risks and uncertainties may emerge
from time to time, and it is not possible to predict all risks and
uncertainties. Factors that may cause actual results to differ
materially from current expectations include, but are not limited
to, various factors beyond management's control including general
economic conditions and other risks, uncertainties and factors set
forth in filings with the SEC. Nothing in this press release should
be regarded as a representation by any person that the
forward-looking statements set forth herein will be achieved or
that any of the contemplated results of such forward-looking
statements will be achieved. You should not place undue reliance on
forward-looking statements, which speak only as of the date they
are made. Immatics undertakes no duty to update these
forward-looking statements.
For more information, please
contact:
Media |
Trophic Communications |
|
Phone: +49 171 3512733 |
|
immatics@trophic.eu |
|
Investor Relations |
|
Sabrina Schecher, Ph.D. |
|
Senior Director, Investor Relations |
|
Phone: +49 89 262002433 |
|
InvestorRelations@immatics.com |
|
Immatics NV (TG:4A3)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immatics NV (TG:4A3)
Historical Stock Chart
From Jul 2023 to Jul 2024